Comparative Pharmacology
Head-to-head clinical analysis: OMEPRAZOLE MAGNESIUM versus PREVACID NAPRAPAC 375 COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMEPRAZOLE MAGNESIUM versus PREVACID NAPRAPAC 375 COPACKAGED.
OMEPRAZOLE MAGNESIUM vs PREVACID NAPRAPAC 375 (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omeprazole magnesium is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, suppressing gastric acid secretion.
Lansoprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase at the secretory surface of the gastric parietal cell. Naproxen, a nonsteroidal anti-inflammatory drug, inhibits cyclooxygenase (COX-1 and COX-2) reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
20 mg orally once daily for 4-8 weeks; for erosive esophagitis 20-40 mg orally once daily for 4-8 weeks; maintenance: 10-20 mg orally once daily; for Helicobacter pylori eradication: 20 mg orally twice daily for 10-14 days in combination with antibiotics.
One tablet (naproxen 375 mg / lansoprazole 15 mg) orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour (fast metabolizers); 2-3 hours (slow metabolizers); clinical context: prolonged in hepatic impairment, no significant accumulation with once-daily dosing due to irreversible inhibition of H+/K+-ATPase.
Naproxen: 12-17 hours (mean 14 hours); allows twice-daily dosing. Lansoprazole: 1.5-2 hours (fast metabolizers) to 3-4 hours (slow metabolizers); clinically negligible due to irreversibly binding to proton pumps.
Renal: 77% as metabolites; biliary/fecal: 16.7% as metabolites; active drug not excreted unchanged.
Naproxen: Approximately 95% excreted in urine as unchanged naproxen (10%) and metabolites (~60% 6-O-desmethylnaproxen and conjugates); <5% in feces. Lansoprazole: Primarily metabolized in liver; metabolites excreted in urine (14-23%) and feces (~22%).
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor/NSAID Combination